Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab.

Daniel Morgensztern,Saiama N. Waqar,Lyudmila Bazhenova,Lori McDermott,Jeff Hutchins,David H. Taylor,Fred L Robinson,Alexa K Dowdell,Brian Piening,Wael A. Harb,Nathan A. Pennell,Roger B. Cohen

Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab.

2020

Daniel Morgensztern
Saiama N. Waqar
Lyudmila Bazhenova
Lori McDermott
Jeff Hutchins
David H. Taylor
Fred L Robinson
Alexa K Dowdell
Brian Piening
Wael A. Harb
Nathan A. Pennell
Roger B. Cohen

9546Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma cell line transfected with gp96-Ig fusion protein. Gp96-Ig functions as an anti...

Keywords:

Viagenpumatucel-L
Nivolumab
Cancer research
Medicine
previously treated
Tumor antigen
non-small cell lung cancer (NSCLC)
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations